At HonorHealth Research Institute, Cardiac Electrophysiologist Rahul Doshi, M.D., this week performed one of the nation’s first procedures to control Afib using a new type of catheter that can deliver ...

Minnesota system treating atrial fibrillation helped sustain Boston Scientific’s streak of bullish results as the company ...

By now, many have seen the commercials with NBA legend Kareem Abdul-Jabbar explaining the importance of seeing ...

A pair of investor calls on Jan. 22 added clarity to the rapidly evolving cardiac ablation market with Abbott Laboratories and Johnson & Johnson providing updates on their pulsed field ablation ...

Abbott expects to launch its first pulsed field ablation (PFA) device outside of the U.S. in 2025, CEO Robert Ford told investors on Wednesday. A company spokesperson said Abbott expects to ...

Boston Scientific posted quarterly organic top-line and adjusted bottom-line growth of 20% and 15%, respectively, fueled by 172% year-over-year growth in electrophysiology, or EP, which includes ...

Abbott Laboratories, the last of the big four players in ... market value and capture more than 70% of the global atrial fibrillation market by 2028. Pulsed Field Ablation: Stunning Growth Shocks the ...

Medtronic stock was down stock was down today after its third-quarter revenue slightly missed the Wall Street analyst consensus.

One year into the U.S. launch of pulsed field ablation systems from Boston Scientific ... Scientific (58%), Medtronic (28%), J&J (11%), and Abbott (3%). In 2026, the survey predicted Boston ...

Farapulse, Boston Scientific’s pulsed field ablation product, fueled year-over-year growth of nearly 171% in the fourth ...